Oncologic outcomes of first-line bevacizumab/FOLFIRI in combination with Ginsenoside-modified nanostructured lipid carrier containing curcumin in unresectable metastatic colorectal cancer patients

Background: The patients with unresectable metastatic colorectal cancer has dismal survival outcomes even though they received standard palliative chemotherapy. Furthermore, current chemotherapy is often associated with various adverse events. A number of studies suggested that curcumin has shown anticancer effects with low toxicity, but there was a lack of long-term survival outcomes of treatment in combination with curcumin and standard chemotherapy in metastatic colorectal cancer patients. This study aimed to evaluate the long-term oncologic outcomes in colorectal cancer patients with unresectable metastases after treatment with first-line bevacizumab/FOLFIRI in combination with a dietary supplement of ginsenoside modified nanostructure lipid carrier containing curcumin (G-NLC).